LAB earnings

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standar

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca

Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024  Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024. "We are laser-focused on optimizing our cost structure, already seeing early integration synerg

SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on July 31, 2024, to discuss second quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US c

Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non-GAAP operating expense reduction of approximately $17 millionOn track to cash flow positive in full-year 2026 with current balance sheet of $464 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced fina

Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company's long-term strategic plan. "Following the completion of the SomaLogic merger, our management team has conducted a comprehensive review of our business as we cont

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902

Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and servicesCombined pro forma revenue for FY2023 totaled $192 million and fortified balance sheet with $565 million in combined pro forma cash, cash equivalents, restricted cash and short-term investments at December 31, 20231 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced financial results for the fourth quarter and fiscal year ended

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on February 28, 2024, to discuss fourth quarter and full year 2023 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conferenc

Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectivesPlanned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc. ("SBI" or the "Company") (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the third quarter ended September 30, 2023. 2023 Selected Financial Results  Quarter Ended Nine Months Ended (Unaudited, in millions, except percentages)September 30, 2023 September 30, 2023Revenue$25.4  $78.2 GAAP gross margin 44.0%

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 7, 2023, to discuss third quarter 2023 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dia

Activates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability1 Estimated combined cash of over $500 million at close2 creates industry-leading balance sheet to fund growth initiatives Standard BioTools increases full year 2023 revenue guidance to $100 - $105 million; SomaLogic reaffirms full year 2023

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools", or the "Company"), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the second quarter ended June 30, 2023. Selected Financial Results (Numbers in millions, except percentages)Quarter EndedJune 30, 2023 Quarter EndedJune 30, 2022Revenue$27.7 $18.8(a)Gross margin49.2% 23.6%Non-GAAP gross margin60.9% 40.2%Operating expenses$31.1 $43.0Non-GAAP operating expenses$25.2 $33.8Operating loss($17.4) ($38.6)Net loss($17.0) ($63.5)Non-GAAP adjusted EBITDA($8.4) ($26.2)Cash and equivalents, restricted ca

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of the market. The Company's management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on August 8, 2023, to discuss second quarter 2023 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US dome

Net cash used in operating activities of $8.5 million, a 55.8% sequential decline from $19.2 million in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year increase in ongoing, core product and service revenue to $24.3 million GAAP product and services margin of 46.6%, an improvement of 567 basis points over fourth quarter 2022; non-GAAP product and service margin grew to 60.9%, a 792 basis point increase over the fourth quarter GAAP operating expenses of $28.7 million, an 11% sequential decline from $32.3 million in the

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the market. The Company's management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on May 9, 2023, to discuss first quarter 2023 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing:

Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring initiatives contributed to a 16% sequential decrease in operating expenses in the fourth quarter; Product and services margin improved sequentially by 620 basis points on a GAAP basis, 520 basis points on a non-GAAP basis Releasing 2023 guidance of flat to moderate growth in core product and service revenues, inclusive of previously disclosed transitory Genomics headwind; Expect 1,100–1,400 basis point GAAP gr

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023, after the close of the market. The Company's management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on February 14, 2023, to discuss fourth quarter and full year 2022 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals interested in listening to the conference c

Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point non-GAAP product and service gross margin improvement to 65-68% by year end 2023, driven by lean transformation, volume growth and value selling On track to achieve positive free cash flow by year-end 2024  Cash, cash equivalents, and short-term investments of $185.2 million  Company to host conference call and webcast today at 5:00 p.m. ET  SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Standard

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of the market. The Company's management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on November 8, 2022, to discuss third quarter 2022 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing:

Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global  Upgraded management team and added board members to bring significant sector and operational expertise to the company  Commenced restructuring program with the explicit goal of returning core business to growth, raising gross margins by approximately 7-10% and substantially reducing operating cash burn   Cash, cash equivalents, and short-term investments expected to provide sufficient runway to generate positive free cash flow by end of 2024 while allowing for strategic M&A  Company to host conference call and webcast today at 4:30 p.m. ET  SOUTH SAN FRANCISCO,